Clinical Trials Browser

Unknown × Immune Checkpoint Inhibitors × Head & Neck × Clear all

NCT05520814 2023-09-21

PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial

Phase 2 Unknown

50 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

441 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04922450 2021-06-10

Clinical Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy for Operable Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

53 enrolled

Head & Neck

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT04769076 2021-02-25

The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma

Phase 2 Unknown

40 enrolled

Head & Neck

Nasopharyngeal Carcinoma